Morgan Stanley Maintains Overweight on Lazard, Lowers Price Target to $55

Morgan Stanley analyst Manan Gosalia maintains Lazard (NYSE:LAZ) with a Overweight and lowers the price target from $61 to $55.

byBenzinga Newsdesk

December 8, 2021

1 minute read

Morgan Stanley analyst Manan Gosalia maintains Lazard (NYSE:LAZ) with a Overweight and lowers the price target from $61 to $55.

BMO Capital Initiates Coverage On Plymouth Industrial REIT with Market Perform Rating, Announces Price Target of $30

By Benzinga Newsdesk

Today, 11:35 PM

BMO Capital analyst John Kim initiates coverage on Plymouth Industrial REIT (NYSE:PLYM) with a Market Perform rating and announces Price Target of $30.

PLYM

Raymond James Maintains Outperform on Meta Platforms, Lowers Price Target to $215

By Benzinga Newsdesk

Today, 11:35 PM

Raymond James analyst Aaron Kessler maintains Meta Platforms (NASDAQ:META) with a Outperform and lowers the price target from $290 to $215.

Cowen & Co. Maintains Outperform on Boeing, Lowers Price Target to $230

By Benzinga Newsdesk

Today, 11:35 PM

Cowen & Co. analyst Cai Rumohr maintains Boeing (NYSE:BA) with a Outperform and lowers the price target from $265 to $230.

5 Short Squeeze Candidates To Watch: Biofrontera Rejoins And Tops List, 2 New Names Enter Leaderboard

By Chris Katje

Today, 11:35 PM

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE: GME) and AMC Entertainment Holdings (NYSE: AMC) are two high-profile examples of short squee

AMC

Morgan Stanley Maintains Overweight on Lazard, Lowers Price Target to $55

Related Posts

BMO Capital Initiates Coverage On Plymouth Industrial REIT with Market Perform Rating, Announces Price Target of $30

Raymond James Maintains Outperform on Meta Platforms, Lowers Price Target to $215

Cowen & Co. Maintains Outperform on Boeing, Lowers Price Target to $230

5 Short Squeeze Candidates To Watch: Biofrontera Rejoins And Tops List, 2 New Names Enter Leaderboard